Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.02M
Last updated: Nov 17, 2026 at 11:04 AM ET
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Competitors
The companies most similar to Liminatus Pharma, Inc. Class A Common Stock are Imunon (IMNN), Lantern Pharma (LTRN) and PharmaCyte Biotech (PMCB). By market cap, Liminatus Pharma, Inc. Class A Common Stock ranks 9th of the 13 companies on this page; Alaunos Therapeutics (TCRT) is the largest at $6.86M.
Peer Comparison
LIMN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| Imunon Inc (IMNN) | $4.08M | N/A | N/A | 0.0% | -131.5% | 0.0% | 0.00% |
| Lantern Pharma Inc (LTRN) | $6.47M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Calidi Biotherapeutics Inc. (CLDI) | $2.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Can Fite Biopharma Ltd ADR (CANF) | $4.30M | N/A | 14.3x | 0.0% | -156.8% | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Pulmatrix Inc (PULM) | $4.71M | N/A | N/A | 0.0% | N/A | -99.9% | 0.00% |
| Galmed Pharmaceuticals Ltd (GLMD) | $4.95M | N/A | N/A | 0.0% | N/A | 0.0% | N/A |
| Creative Medical Technology Holdings Inc (CELZ) | $4.01M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Alaunos Therapeutics Inc (TCRT) | $6.86M | N/A | N/A | 0.0% | N/A | -25.0% | 0.00% |
| Peer median | $4.26M | N/A | 14.3x | 0.0% | -144.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Liminatus Pharma, Inc. Class A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Imunon Inc (IMNN) | Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious... | IMNN competitors |
| Lantern Pharma Inc (LTRN) | Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics... | LTRN competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| Calidi Biotherapeutics Inc. (CLDI) | Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. | CLDI competitors |
| Can Fite Biopharma Ltd ADR (CANF) | Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer... | |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| Pulmatrix Inc (PULM) | Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases... | PULM competitors |
| Galmed Pharmaceuticals Ltd (GLMD) | Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases. | |
| Creative Medical Technology Holdings Inc (CELZ) | Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics... | CELZ competitors |
| Alaunos Therapeutics Inc (TCRT) | Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring... | TCRT competitors |
Frequently Asked Questions About LIMN
Who are Liminatus Pharma, Inc. Class A Common Stock's main competitors?
The companies most similar to Liminatus Pharma, Inc. Class A Common Stock include Imunon (IMNN), Lantern Pharma (LTRN), PharmaCyte Biotech (PMCB), Processa Pharmaceuticals (PCSA) and Calidi Biotherapeutics (CLDI), listed from the closest match.
Who is Liminatus Pharma, Inc. Class A Common Stock's biggest competitor?
Alaunos Therapeutics (TCRT) is the largest of the similar companies at $6.86M; Imunon (IMNN) is the closest match by business profile, size, sector and industry.
How does LIMN stock compare with its competitors?
LIMN's net margin is 0.0% against a peer median of 0.0%.
Which of Liminatus Pharma, Inc. Class A Common Stock's competitors pays a higher dividend?
Liminatus Pharma, Inc. Class A Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Liminatus Pharma, Inc. Class A Common Stock bigger than its competitors?
No. Liminatus Pharma, Inc. Class A Common Stock is 9th by market cap among the 13 companies on this page; the largest is Alaunos Therapeutics (TCRT) at $6.86M.
LIMN pages: Overview, Financials, Competitors